Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Akari Therapeutics ADR (NQ: AKTX )

1.630 USD -0.010 (-0.61%)
Streaming Delayed Price Updated: 3:59 PM EDT, Aug 3, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 56,762
Open 1.640
Bid (Size) 1.620 (4)
Ask (Size) 1.640 (6)
Prev. Close 1.640
Today's Range 1.600 - 1.670
52wk Range 1.420 - 4.210
Shares Outstanding 3,847,331,923
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Akari Therapeutics Announces Private Placement
From GlobeNewswire News Releases
Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress
From GlobeNewswire News Releases

Performance

YTD
-9.94%
-9.94%
1 Month
-4.12%
-4.12%
3 Month
-20.49%
-20.49%
6 Month
-37.31%
-37.31%
1 Year
-15.98%
-15.98%

More News

Read More
Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid
From GlobeNewswire News Releases
Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at American Academy of Dermatology Association Virtual Meeting Experience
From GlobeNewswire News Releases
Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress
From GlobeNewswire News Releases
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)
From GlobeNewswire News Releases
Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma
From GlobeNewswire News Releases
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Tags JAGX EVAX SNGX
From Benzinga
Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis
From GlobeNewswire News Releases
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Tags Markets Market News PRQR
From Benzinga
Akari Therapeutics' Nomacopan Secures Expediated Review Tag For Blistering Skin Disorder
Tags News Skin Disorder FDA
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.